➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Moodys
Baxter
Dow
McKesson

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Norepinephrine Bitartrate In 5% Dextrose patents expire, and when can generic versions of Norepinephrine Bitartrate In 5% Dextrose launch?

Norepinephrine Bitartrate In 5% Dextrose is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.

The generic ingredient in NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is norepinephrine bitartrate. There are five drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate In 5% Dextrose

A generic version of NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE was approved as norepinephrine bitartrate by TEVA PHARMS USA on March 3rd, 2003.

  Try it Free

Summary for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
Drug patent expirations by year for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare Corp NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE norepinephrine bitartrate SOLUTION;INTRAVENOUS 214313-001 Jan 15, 2021 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Baxter Hlthcare Corp NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE norepinephrine bitartrate SOLUTION;INTRAVENOUS 214313-002 Jan 15, 2021 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Moodys
Baxter
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.